公开(公告)号：EP2704713B1

公开(公告)日：2017-01-18

申请号：EP12720761.1

申请日：2012-05-04

申请人： Novartis AG ,  Sloan-Kettering Institute for Cancer Research

发明人： DANIEL, Dylan ,  JOYCE, Johanna ,  SUTTON, James

IPC分类号： A61K31/4439 ,  A61K45/06 ,  C07D417/14 ,  A61P35/00

CPC分类号： A61K31/4439 ,  A61K31/175 ,  A61K31/4545 ,  A61K31/675 ,  A61K39/3955 ,  A61K45/06 ,  C07D417/12 ,  C07D417/14

公开(公告)号：EP2704713A1

公开(公告)日：2014-03-12

申请号：EP12720761.1

申请日：2012-05-04

申请人： Novartis AG ,  Sloan-Kettering Institute for Cancer Research

发明人： DANIEL, Dylan ,  JOYCE, Johanna ,  SUTTON, James

IPC分类号： A61K31/4439 ,  A61K45/06 ,  C07D417/14 ,  A61P35/00

CPC分类号： A61K31/4439 ,  A61K31/175 ,  A61K31/4545 ,  A61K31/675 ,  A61K39/3955 ,  A61K45/06 ,  C07D417/12 ,  C07D417/14

摘要： The present invention provides a compound of formula I; where in R1 is an alkyl pyrazole or an alkyl carboxamide, and R2 is a hydroxycycloalkyl; or a pharmaceutically acceptable salt thereof, and compositions containing these compounds, for use to treat a brain tumor, particularly glioblastoma. The invention provides effective treatment of a brain tumor and can be used by oral administration of a compound of Formula I as further described herein. Gene signatures correlated with successful treatment using these methods are also disclosed.